Movement Alert｜CSPC Pharmaceutical Falls 3.08% in Regular Trading, Pharmaceutical Sector Faces Broad Selling Pressure After Prior Session Surge

Market Focus06-30 14:35

On June 30, CSPC Pharmaceutical fell 3.08% in regular trading, trading at HK$6.93/share, with turnover of HK$481 million. The decline comes amid uniform weakness across the pharmaceutical sector, with peers including Asymchem down 8.97%, Luye Pharma down 6.38%, Hansoh Pharma down 3.23%, and Hengrui Pharma down 2.15%.

Notably, the stock had surged over 10% in the prior session after announcing that its core ADC drug SYS6010 in combination with enlonstobart had officially commenced a Phase III clinical trial in China for the treatment of driver-gene-negative non-small cell lung cancer, with the first subject enrollment planned for July. Today's retreat partially reflects profit-taking pressure following that sharp rally, compounded by sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189543018?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 14:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189543018","market":"us","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Falls 3.08% in Regular Trading, Pharmaceutical Sector Faces Broad Selling Pressure After Prior Session Surge","media":"Market Focus","content":"<p><p>On June 30, CSPC Pharmaceutical fell 3.08% in regular trading, trading at HK$6.93/share, with turnover of HK$481 million. The decline comes amid uniform weakness across the pharmaceutical sector, with peers including Asymchem down 8.97%, Luye Pharma down 6.38%, Hansoh Pharma down 3.23%, and Hengrui Pharma down 2.15%.</p><p>Notably, the stock had surged over 10% in the prior session after announcing that its core ADC drug SYS6010 in combination with enlonstobart had officially commenced a Phase III clinical trial in China for the treatment of driver-gene-negative non-small cell lung cancer, with the first subject enrollment planned for July. Today's retreat partially reflects profit-taking pressure following that sharp rally, compounded by sector-wide headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Falls 3.08% in Regular Trading, Pharmaceutical Sector Faces Broad Selling Pressure After Prior Session Surge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Falls 3.08% in Regular Trading, Pharmaceutical Sector Faces Broad Selling Pressure After Prior Session Surge\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 14:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, CSPC Pharmaceutical fell 3.08% in regular trading, trading at HK$6.93/share, with turnover of HK$481 million. The decline comes amid uniform weakness across the pharmaceutical sector, with peers including Asymchem down 8.97%, Luye Pharma down 6.38%, Hansoh Pharma down 3.23%, and Hengrui Pharma down 2.15%.</p><p>Notably, the stock had surged over 10% in the prior session after announcing that its core ADC drug SYS6010 in combination with enlonstobart had officially commenced a Phase III clinical trial in China for the treatment of driver-gene-negative non-small cell lung cancer, with the first subject enrollment planned for July. Today's retreat partially reflects profit-taking pressure following that sharp rally, compounded by sector-wide headwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1189543018","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189543018","pubTimestamp":1782801340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, CSPC Pharmaceutical fell 3.08% in regular trading, trading at HK$6.93/share, with turnover of HK$481 million. The decline comes amid uniform weakness across the pharmaceutical sector,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"异动快讯|石药制药常规交易跌3.08%医药板块在前一交易日大涨后面临广泛抛压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On June 30, CSPC Pharmaceutical fell 3.08% in regular trading, trading at HK$6.93/share, with turnover of HK$481 million. The decline comes amid uniform weakness across the pharmaceutical sector, with peers including Asymchem down 8.97%, Luye Pharma down 6.38%, Hansoh Pharma down 3.23%, and Hengrui Pharma down 2.15%.Notably, the stock had surged over 10% in the prior session after announcing that its core ADC drug SYS6010 in combination with enlonstobart had officially commenced a Phase III clinical trial in China for the treatment of driver-gene-negative non-small cell lung cancer, with the first subject enrollment planned for July. Today's retreat partially reflects profit-taking pressure following that sharp rally, compounded by sector-wide headwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189543018","isCrawlerRequest":true}